EU/3/15/1490: Orphan designation for the treatment of non-infectious uveitis

Triamcinolone acetonide

Overview

On 21 May 2015, orphan designation (EU/3/15/1490) was granted by the European Commission to S-cubed Limited, United Kingdom, for triamcinolone acetonide for the treatment of non-infectious uveitis.

The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in January 2019.

Key facts

Active substance
Triamcinolone acetonide
Intended use
Treatment of non-infectious uveitis
Orphan designation status
Positive
EU designation number
EU/3/15/1490
Date of designation
21/05/2015
Sponsor

S-cubed Pharmaceutical Services ApS
David Balfours Gade 4, St., Tv
Copenhagen K
Hovedstaden 1402
Denmark
Tel. +45 3145 2916
E-mail: info@s-cubed-global.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating